Key result
Antiarrhythmic drugs are frequently required as adjunctive treatment in patients with implantable cardioverter defibrillators, necessitating careful management of potential drug-device interactions.
Why the study?
Does adjunctive treatment with antiarrhythmic drugs improve outcomes in patients with implantable cardioverter defibrillators?
Does adjunctive treatment with antiarrhythmic drugs improve outcomes in patients with implantable cardioverter defibrillators?
This review outlines the indications, options, and potential drug-device interactions for antiarrhythmic drug therapy in patients with implantable cardioverter defibrillators.
Clinicians must monitor for drug-device interactions with adjunctive AADs in ICD patients; leaves open optimal strategies pending prospective trials.
The transvenous implantable cardioverter defibrillator (ICD) has emerged as the primary therapy for patients at high risk of life-threatening ventricular arrhythmias. A high number of ICD recipients will require subsequent adjunctive treatment with antiarrhythmic drugs (AADs). This review provides an overview of potential reasons for AAD initiation, candidates for treatment, current medical options, and possible drug-device interactions.
No takes yet. Share an insight, caveat, or question.
Herendael et al. (2010) conducted a review in Life-threatening ventricular arrhythmias in ICD recipients. Antiarrhythmic drugs was evaluated. Antiarrhythmic drugs are frequently required as adjunctive treatment in patients with implantable cardioverter defibrillators, necessitating careful management of potential drug-device interactions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: